FBRX logo

FBRX
Forte Biosciences Inc

2,964
Mkt Cap
$522.42M
Volume
200.00
52W High
$35.80
52W Low
$6.13
PE Ratio
-5.09
FBRX Fundamentals
Price
$26.80
Prev Close
$26.66
Open
$27.04
50D MA
$28.43
Beta
0.66
Avg. Volume
227,521.88
EPS (Annual)
-$4.71
P/B
5.66
Rev/Employee
$0.00
$324.40
Loading...
Loading...
News
all
press releases
Stock Traders Purchase High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX)
Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) saw some unusual options trading on Wednesday. Investors acquired 30,205 call options on the stock. This represents an increase of 1,663% compared to the average volume of 1,713 call options...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Update
Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 892,176...
MarketBeat·15d ago
News Placeholder
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX)
Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the target of unusually large options trading activity on Wednesday. Investors purchased 30,205 call options on the company. This...
MarketBeat·15d ago
News Placeholder
Brookline Capital Markets Predicts FBRX FY2026 Earnings
Forte Biosciences, Inc. (NASDAQ:FBRX - Free Report) - Analysts at Brookline Capital Markets decreased their FY2026 earnings estimates for Forte Biosciences in a research note issued on Monday, April 6th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings pe...
MarketBeat·22d ago
News Placeholder
Forte Biosciences Announces Pricing of $150 Million Public Offering
Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936...
Business Wire·23d ago
News Placeholder
Forte Biosciences Announces Proposed Public Offering
Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public...
Business Wire·23d ago
News Placeholder
Analysts Issue Forecasts for FBRX FY2030 Earnings
Forte Biosciences, Inc. (NASDAQ:FBRX - Free Report) - Investment analysts at Brookline Capital Markets issued their FY2030 EPS estimates for shares of Forte Biosciences in a research note issued to investors on Monday, April 6th. Brookline Capital Markets analyst K. Raja expects that the company wil...
MarketBeat·23d ago
News Placeholder
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)
Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the recipient of some unusual options trading on Wednesday. Traders acquired 30,205 call options on the company. This represents an...
MarketBeat·29d ago
News Placeholder
Forte Biosciences (NASDAQ:FBRX) Announces Quarterly Earnings Results
Forte Biosciences (NASDAQ:FBRX - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus...
MarketBeat·1mo ago
News Placeholder
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its full year 2025...
Business Wire·1mo ago
<
1
2
...
>

Latest FBRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.